BACKGROUND: Concurrent chemoradiation therapy (CRT) is the current standard of care for @entity1 with locally advanced @entity2220 ; however, little has been reported about the impact of @entity470 ( @entity470 ) mutation on CRT efficacy. METHODS: From 2006 to 2013, we retrospectively screened 104 unresectable stage III @entity420 @entity1 who were examined for @entity470 mutation status and received definitive concurrent CRT consisting of @entity902 doublet chemotherapy in first-line setting and compared the clinical outcomes and recurrence patterns according to mutation status. RESULTS: Among 104 @entity1 , @entity470 mutation was detected in 29 (28%). The overall response rate did not differ between @entity470 -mutant and wild-type @entity1 (72.4% versus 72.0%, p = 0.607). The median progression-free survival in concurrent CRT was significantly shorter in @entity470 -mutant @entity1 than in wild-type @entity1 (9.8 [95% confidence interval, CI: 7.6-19.0] versus 16.5 [95% CI: 11.8-19.9] months, p = 0.041). The 2-year recurrence-free survival rate was 7.7% and 28.1% in @entity470 -mutant and wild-type @entity1 , respectively (p = 0.028). Distant metastases were more frequently identified as the first recurrence site in @entity470 -mutant @entity1 than in wild-type @entity1 (76% versus 40%, p = 0.001). The brain was the most often affected site in @entity470 -mutant @entity1 (35%). However, locoregional recurrence was less common in @entity470 -mutant @entity1 than in the wild-type population (14% versus 35%, p = 0.027). Overall survival was similar between @entity470 -mutant and wild-type @entity1 (51.1 [95% CI: 28.2-70.2] versus 42.9 [95% CI: 35.3 to not available] months, p = 0.637). Among the @entity470 wild-type population who were examined for @entity984 mutation, @entity984 -mutant @entity1 had significantly worse overall survival than @entity984 wild-type @entity1 (21.6 versus 49.8 months, p = 0.024). CONCLUSION: Concurrent CRT resulted in shorter progression-free survival in @entity470 -mutant stage III @entity420 @entity1 than in wild-type @entity1 , mainly because of distant metastasis relapse, regardless of better local control. Because of these distinct biological features, a different strategy, including @entity470 - @entity4149 kinase inhibitors for @entity470 -mutant locally advanced @entity420 @entity1 receiving definitive CRT may be needed.

XXXX Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity984 :: ('3845', 'Gene') :: ['Kras'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma']
@entity470 :: (1956,Gene) :: ['EGFR']
